Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype [4]

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 9, 2006, Pages 3227-3228

  Geist, Marcus J P ^a   Egerer, Gerlinde ^a   Burhenne, Jürgen ^a   Mikus, Gerd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2C9 2; CYTOCHROME P450 3A4; GLIPIZIDE; PHENYTOIN; TOLBUTAMIDE; UNCLASSIFIED DRUG; VORICONAZOLE; WARFARIN;

ALLELE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PYRIMIDINES; TRIAZOLES;

EID: 33748689372     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00551-06     Document Type: Letter

References (10)

1. Burian, M., S. Grosch, I. Tegeder, and G. Geisslinger. 2002. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br. J. Clin. Pharmacol. 54:518-521.
2. Hyland, R., B. C. Jones, and D. A. Smith. 2003. Identification of the cytochromc P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-547.
3. Lee, C. R., J. A. Goldstein, and J. A. Pieper. 2002. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251-263.
4. Mikus, G., V. Schöwel, M. Drzewinska, J. Rengelshausen, R. Ding, K. D. Riedel, J. Burhenne, J. Weiss, T. Thomsen, and W. E. Haefeli. Potent CYP2C19 genotype related interaction between voriconazole and the CYP3A4 inhibitor ritonavir. Clin. Pharmacol. Ther., in press.
5. Pennick, G. J., M. Clark, D. A. Sutton, and M. G. Rinaldi. 2003. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob. Agents Chemother. 47:2348-2350.
6. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
7. Rengelshausen, J., M. Banfield, K. D. Riedel, J. Burhenne, J. Weiss, T. Thomsen, I. Walter-Sack, W. E. Haefeli, and G. Mikus. 2005. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin. Pharmacol. Ther. 78:25-33.
8. Shah, V. P., K. K. Midha, J. W. Findlay, H. M. Hill, J. D. Hulse, I. J. McGilveray, G. McKay, K. J. Miller, R. N. Patnaik, M. L. Powell, A. Tonelli, C. T. Viswanathan, and A. Yacobi. 2000. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17:1551-1557.
9. Shimizu, T., H. Ochiai, F. Asell, H. Shimizu, R. Saitoh, Y. Hama, J. Katada, M. Hashimoto, H. Matsui, K. Taki, T. Kaminuma, M. Yamamoto, Y. Aida, A. Ohashi, and N. Ozawa. 2003. Bioinformatics research on inter-racial difference in drug metabolism. I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab. Pharmacokinet. 18:48-70.
10. Wilkinson, G. R. 2005. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352:2211-2221.